October 25, 2019 10:34 AM EDTUpdated 03:03 PM

Christopher Haqq joins Elicio to hunt father's RAS cancer; Kronos expands top team with Gilead, Baylor vets

ENDPOINTS

Christopher Haqq’s father taught him how to build volcanoes in their backyard. He was a beloved chemistry teacher for 30 years who inspired many students, Haqq says, and sent him down a path through volcanoes and up into oncology.

Christopher Haqq

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Christopher Haqq joins Elicio to hunt father's RAS cancer; Kronos expands top team with Gilead, Baylor vets

ENDPOINTS

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Christo­pher Haqq joins Eli­cio to hunt fa­ther's RAS can­cer; Kro­nos ex­pands top team with Gilead, Bay­lor vets

ENDPOINTS

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Christopher Haqq joins Elicio to hunt father's RAS cancer; Kronos expands top team with Gilead, Baylor vets

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?